Implicit licenses clinical stage antibody program from Lilly

[News]

Implicit Bioscience Ltd has announced the acquisition of the clinical-stage monoclonal antibody IC14 from Eli Lilly and Company. Implicit has paid an undisclosed consideration combining cash and stock to Lilly. Lilly will also receive a royalty on future IC14 sales.

More... (http://www.news-medical.net/?id=46227)